Results 31 to 40 of about 779,609 (165)

Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. [PDF]

open access: yesAliment Pharmacol Ther, 2021
Summary Background Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT‐P13, an infliximab biosimilar, was approved for clinical use.
Hanzel J   +4 more
europepmc   +5 more sources

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. [PDF]

open access: yesCrohns Colitis 360, 2022
Lay Summary Patients with inflammatory bowel disease were switched from the originator infliximab to the biosimilar CT-P13. Before and after switching they filled in questionnaires.
Pierik MJ   +11 more
europepmc   +4 more sources

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis. [PDF]

open access: yesJ Clin Med, 2021
CT-P13 is an infliximab biosimilar approved for indications including ankylosing spondylitis (AS); the approved maintenance regimen is 5 mg/kg infused every 6–8 weeks. In clinical practice, modifications to infliximab dose and/or infusion interval can be
Lee SS   +6 more
europepmc   +2 more sources

Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). [PDF]

open access: yesRheumatol Adv Pract, 2021
Objective Report results from PERSIST, a real-life, observational, prospective cohort study of CT-P13, an infliximab (IFX) biosimilar, for treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) who ...
Taylor PC   +8 more
europepmc   +2 more sources

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

open access: yesمجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil   +2 more
doaj   +1 more source

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. [PDF]

open access: yesWorld J Clin Cases, 2021
In recent years, biological therapies have revolutionized the management of inflammatory bowel disease (IBD); however, they are expensive. The development of biosimilar products has allowed us to reduce healthcare costs and improve patients' access to these treatments.
Huguet JM   +7 more
europepmc   +5 more sources

Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease [PDF]

open access: yes, 2021
Background: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator.
Smits, L.J.T.   +12 more
core   +1 more source

Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. [PDF]

open access: yesBioDrugs, 2020
Objective The aim was to evaluate long-term drug retention, discontinuation, efficacy and safety of CT-P13 and reference infliximab in patients with rheumatoid arthritis (RA) enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry ...
Kim HA   +6 more
europepmc   +4 more sources

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence

open access: yesFrontiers in Pharmacology, 2022
Background: Many pediatric inflammatory bowel disease (IBD) patients are now using biosimilars of anti-tumor necrosis factor-α (TNF-α), with increasing trends in recent years.
Valeria Dipasquale   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy